Completed PHASE3 INTERVENTIONAL NCT00209950

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

A Prospective Open-Label Extension Study (to Study 99784) of Gaboxadol in Primary Insomnia

Sponsor: H. Lundbeck A/S

Interventions Gaboxadol

Updated 5 times since 2017 Last updated: Mar 29, 2007 Started: Jul 31, 2004 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Insomnia, this trial is completed. The trial is conducted by H. Lundbeck A/S and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S

Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Regensburg, Germany